Search

Your search keyword '"Clauw D"' showing total 388 results
Start Over Author "Clauw D"
388 results on '"Clauw D"'

2. POS0310 BARICITINIB MAY REDUCE CO-EXISTING FIBROMYALGIA IN PEOPLE WITH RHEUMATOID ARTHRITIS: AN ULTRA-HIGH RESOLUTION MRI BRAIN STUDY

Author

Basu, N., primary, Al-Wasity, S., additional, Brock, J., additional, Stefanov, K., additional, Sunzini, F., additional, Aldehmi, N., additional, Arnott, M., additional, Porter, D., additional, Keith, G., additional, Kaplan, C., additional, Schrepf, A., additional, Mc Innes, I. B., additional, and Clauw, D., additional

Published
2024
Full Text
View/download PDF

3. Concerns about the taxonomy, definition and coding of fibromyalgia syndrome in ICD-11 : the potential for negative consequences for patient care and research

Author

Haeuser, W., Clauw, D. J., Wolfe, F., Sarzi-Puttini, P., Ablin, J. N., Usui, C., Littlejohn, G. O., Morlion, B., Kosek, Eva, Fors, E. A., Forseth, K. M. Oien, Fitzcharles, M-A, Haeuser, W., Clauw, D. J., Wolfe, F., Sarzi-Puttini, P., Ablin, J. N., Usui, C., Littlejohn, G. O., Morlion, B., Kosek, Eva, Fors, E. A., Forseth, K. M. Oien, and Fitzcharles, M-A

Published
2022
Full Text
View/download PDF

4. FDA/Arthritis Foundation osteoarthritis drug development workshop recap:assessment of long-term benefit

Author

Kim, J. S. (Jason S.), Borges, S. (Silvana), Clauw, D. J. (Daniel J.), Conaghan, P. G. (Philip G.), Felson, D. T. (David T.), Fleming, T. R. (Thomas R.), Glaser, R. (Rachel), Hart, E. (Elizabeth), Hochberg, M. (Marc), Kim, Y. (Yura), Kraus, V. B. (Virginia B.), Lapteva, L. (Larissa), Li, X. (Xiaojuan), Majumdar, S. (Sharmila), McAlindon, T. E. (Timothy E.), Mobasheri, A. (Ali), Neogi, T. (Tuhina), Roemer, F. W. (Frank W.), Rothwell, R. (Rebecca), Shibuya, R. (Robert), Siegel, J. (Jeffrey), Simon, L. S. (Lee S.), Spindler, K. P. (Kurt P.), Nikolov, N. P. (Nikolay P.), Kim, J. S. (Jason S.), Borges, S. (Silvana), Clauw, D. J. (Daniel J.), Conaghan, P. G. (Philip G.), Felson, D. T. (David T.), Fleming, T. R. (Thomas R.), Glaser, R. (Rachel), Hart, E. (Elizabeth), Hochberg, M. (Marc), Kim, Y. (Yura), Kraus, V. B. (Virginia B.), Lapteva, L. (Larissa), Li, X. (Xiaojuan), Majumdar, S. (Sharmila), McAlindon, T. E. (Timothy E.), Mobasheri, A. (Ali), Neogi, T. (Tuhina), Roemer, F. W. (Frank W.), Rothwell, R. (Rebecca), Shibuya, R. (Robert), Siegel, J. (Jeffrey), Simon, L. S. (Lee S.), Spindler, K. P. (Kurt P.), and Nikolov, N. P. (Nikolay P.)

Abstract

Objective: To summarize proceedings of a workshop convened to discuss the current state of science in the disease of osteoarthritis (OA), identify the knowledge gaps, and examine the developmental and regulatory challenges in bringing these products to market. Design: Summary of the one-day workshop held virtually on June 22nd, 2021. Results: Speakers selected by the Planning Committee presented data on the current approach to assessment of OA therapies, biomarkers in OA drug development, and the assessment of disease progression and long-term benefit. Conclusions: Demonstrated by numerous failed clinical trials, OA is a challenging disease for which to develop therapeutics. The challenge is magnified by the slow time of onset of disease and the need for clinical trials of long duration and/or large sample size to demonstrate the effect of an intervention. The OA science community, including academia, pharmaceutical companies, regulatory agencies, and patient communities, must continue to develop and test better clinical endpoints that meaningfully reflect disease modification related to long-term patient benefit.

Published
2022

37. (319) Regional gray matter density differences predict classification of chronic pelvic pain and fibromyalgia: findings from the MAPP Research Network

Author

Martucci, K., primary, Bagarinao, E., additional, Johnson, K., additional, Ichesco, E., additional, Farmer, M., additional, Labus, J., additional, Ness, T., additional, Harris, R., additional, Deutsch, G., additional, Apkarian, A., additional, Mayer, E., additional, Clauw, D., additional, and Mackey, S., additional

Published
2014
Full Text
View/download PDF

41. Fibromyalgia syndrome.

Author

Simon L., Crofford L., Williams D., Mease P.J., Arnold L.M., Spaeth M., Bennett R., Boonen A., Buskila D., Carville S., Chappell A., Choy E., Clauw D., Dadabhoy D., Gendreau M., Goldenberg D., Littlejohn G., Martin S., Perera P., Russell I.J., Simon L., Crofford L., Williams D., Mease P.J., Arnold L.M., Spaeth M., Bennett R., Boonen A., Buskila D., Carville S., Chappell A., Choy E., Clauw D., Dadabhoy D., Gendreau M., Goldenberg D., Littlejohn G., Martin S., Perera P., and Russell I.J.

Abstract

The fibromyalgia syndrome (FM) workshop at OMERACT 8 continued the work initiated in the first FM workshop at OMERACT 7 in 2004. The principal objectives were to work toward consensus on core domains for assessment in FM studies, evaluate the performance quality of outcome measures used in a review of recent trials in FM, and discuss the research agenda of the FM working group. An initiative to include the patient perspective on identification and prioritization of domains, consisting of focus groups and a patient Delphi exercise, was completed prior to OMERACT 8. Patient-identified domains were, for the most part, similar to those identified by clinician-investigators in terms of symptoms and relative importance. However, patients identified certain domains, such as stiffness, that were not included by physicians, and emphasized the importance of domains such as dyscognition and impaired motivation. Many of the principal domains agreed upon by the clinician-investigators, patients, and OMERACT participants, including pain, fatigue, sleep, mood, and global measures, have been used in clinical trials and performed well when viewed through the OMERACT filter. The research agenda items reviewed and approved for continued study included development of objective "biomarkers" in FM, development of a responder index for FM, and coordination with the WHO's International Classification of Functioning Disability and Health (ICF) Research Branch and the US National Institutes of Health's Patient Reported Outcome Measures Information System network (PROMIS) to develop improved measures of function, quality of life, and participation. The OMERACT process has provided a framework for identification of key domains to be assessed and a path toward validation and standardization of outcome measures for clinical trials in FM.

Published
2012

43. Pain Mechanisms and Centralized Pain in Temporomandibular Disorders.

Author

Harper, D. E., Schrepf, A., and Clauw, D. J.

Subjects
PHYSIOLOGICAL aspects of pain, TEMPOROMANDIBULAR disorders, NOCICEPTIVE pain, INFLAMMATION, CENTRAL nervous system, ETIOLOGY of diseases
Abstract

Until recently, most clinicians and scientists believed that the experience of pain is perceptually proportional to the amount of incoming peripheral nociceptive drive due to injury or inflammation in the area perceived to be painful. However, many cases of chronic pain have defied this logic, leaving clinicians perplexed as to how patients are experiencing pain with no obvious signs of injury in the periphery. Conversely, there are patients who have a peripheral injury and/or inflammation but little or no pain. What makes some individuals experience intense pain with minimal peripheral nociceptive stimulation and others experience minimal pain with serious injury? It is increasingly well accepted in the scientific community that pain can be generated and maintained or, through other mechanisms, suppressed by changes in the central nervous system, creating a complete mismatch between peripheral nociceptive drive and perceived pain. In fact, there is no known chronic pain condition where the observed extent of peripheral damage reproducibly engenders the same level of pain across individuals. Temporomandibular disorders (TMDs) are no exception. This review focuses on the idea that TMD patients range on a continuum-from those whose pain is generated peripherally to those whose pain is centralized (i.e., generated, exacerbated, and/or maintained by central nervous system mechanisms). This article uses other centralized chronic pain conditions as a guide, and it suggests that the mechanistic variability in TMD pain etiology has prevented us from adequately treating many individuals who are diagnosed with the condition. As the field moves forward, it will be imperative to understand each person's pain from its own mechanistic standpoint, which will enable clinicians to deliver personalized medicine to TMD patients and eventually provide relief in even the most recalcitrant cases. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results